Registered title, quoted from ClinicalTrials.gov
Watch and Wait for NeoAdjuvant Concurrent Radiochemotherapy Combined With Camrelizumab in Patients With Resectable ESCC
An open trial on oesophageal squamous cell carcinoma, registered on ClinicalTrials.gov. Led by Zhejiang Cancer Hospital; 2 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 3
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
- Lead sponsorZhejiang Cancer Hospital浙江省肿瘤医院HangzhouHospital page
- Study siteFirst Affiliated Hospital, Zhejiang University浙江大学医学院附属第一医院HangzhouHospital page
- Study siteNingbo Medical Center Lihuili Hospital宁波市医疗中心李惠利医院NingboHospital page
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT05507411, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 3
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (3 points)Hide the checklist
18 years to 75 years; sex: all
Registered eligibility fields
Participant type and target disease characteristics Eastern Collaboration Group (ECOG) physical status score 0-1; Histologically confirmed esophageal cancer with lesions located in the thoracic esophagus, AJCC/UICC esophageal cancer staging (eighth edition) clinical stage cT2-4aNanyM0, or cT1-3N+M0; Presence of measurable lesions according to RECIST criteria; Participants must have tumor tissue samples available for PD-L1 IHC testing; No major associated pathological conditions that increase the risk of surgery to unacceptable levels. Such as: esophageal perforation and active esophageal bleeding, obvious trachea, thoracic large blood vessel invasion; According to the surgeon's assessment, the total lung function can withstand the proposed esophageal cancer resection;
Inclusion criterion 2
Age and reproductive status Age ≥18 years old and ≤75 years old; Females of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity of 25 IU/L or equivalent for HCG) within 24 hours prior to initiation of study treatment; Women must be non-nursing;
Inclusion criterion 3
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; day-to-day activity level; blood tests: counts, liver and kidney function; scans and measurable lesions; other conditions the trial excludes; pregnancy, breastfeeding and contraception.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT05507411, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Sign the informed consent. Participants signed and dated written informed consent. Informed consent must be signed prior to any protocol-related procedures that are not part of the participant's routine medical care; Participants must be willing and able to comply with scheduled visits, treatment regimens, and laboratory tests;
- Participant type and target disease characteristics Eastern Collaboration Group (ECOG) physical status score 0-1; Histologically confirmed esophageal cancer with lesions located in the thoracic esophagus, AJCC/UICC esophageal cancer staging (eighth edition) clinical stage cT2-4aNanyM0, or cT1-3N+M0; Presence of measurable lesions according to RECIST criteria; Participants must have tumor tissue samples available for PD-L1 IHC testing; No major associated pathological conditions that increase the risk of surgery to unacceptable levels. Such as: esophageal perforation and active esophageal bleeding, obvious trachea, thoracic large blood vessel invasion; According to the surgeon's assessment, the total lung function can withstand the proposed esophageal cancer resection;
- Age and reproductive status Age ≥18 years old and ≤75 years old; Females of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity of 25 IU/L or equivalent for HCG) within 24 hours prior to initiation of study treatment; Women must be non-nursing;
Exclusion Criteria:
- Medical condition There is locally advanced unresectable (regardless of stage) or metastatic disease.
Participants with Grade ≥2 Peripheral Neuropathy; Participants with active, known or suspected autoimmune disease. Participants with type 1 diabetes, hypothyroidism requiring only hormone replacement therapy, skin disorders that do not require systemic treatment (eg, vitiligo, psoriasis, or alopecia), or disorders that are not expected to recur in the absence of external stimuli are eligible to be enrolled; Participants requiring systemic therapy with glucocorticoids (>10 mg prednisone equivalent daily) or other immuno suppressive drugs within 14 days prior to treatment. In the absence of active autoimmune disease, inhaled or topical steroids and adrenal hormone replacement therapy at >10 mg prednisone-equivalent daily are permitted; Known history of positive human immuno deficiency virus (HIV) test or known acquired immuno deficiency syndrome (AIDS); Participants with serious or uncontrolled medical illness; previous/concomitant therapy; Received chest radiotherapy, chemotherapy, immunotherapy, or surgery of the esophagus, esophagus and gastric junction, or stomach prior to the start of the trial.
Patients with severe cardiovascular or pulmonary disease, interstitial pneumonia, or previous history of interstitial pneumonia; Patients with obvious esophageal ulcers, moderate pain in the chest and back, and esophageal perforation symptoms; Physical examination and laboratory test results
Laboratory screening values must meet the following criteria (using CTCAE 4th edition):
i) WBC < 2000/μL; ii) Neutrophils < 1500/μL; iii) Platelets < 100x103/μL; iv) Hemoglobin < 9.0 g/dL; v) Serum creatinine <1.5 x ULN or calculated creatinine clearance (CrCl) < 50 mL/min (using Cockcroft-Gault formula); vi) AST >3.0 x ULN; vii) ALT > 3.0 x ULN; viii) Total bilirubin >1.5 x ULN (except for Gilbert syndrome participants, who had total bilirubin < 3.0 x ULN); Participants had active hepatitis B (positive for hepatitis B surface antigen [HBsAg] or positive for hepatitis C virus (HCV) (positive for HCV RNA); i) Participants with previous or recovered HBV infection (defined as having hepatitis B core antibody [HBcAb] and no HBsAg) are eligible. HBV DNA from these patients must be obtained prior to treatment. Participants who are HBV carriers or require antiviral therapy are not eligible; ii) Participants positive for HCV antibodies are eligible only if PCR for HCV RNA is negative.; Active malignancy within the past 3 years, except for locally curable cancers that have been significantly cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast; Participants with serious or uncontrolled medical conditions; Allergic Reactions and Adverse Drug Reactions; History of allergic reactions or hypersensitivity reactions to study drug components Other exclusion criteria; Patients who do not understand trial requirements, or who may not comply with trial requirements; Active infection requiring systemic therapy 14 days prior to first dose Some obvious diseases that the researchers believe should be excluded from this study;
Quoted from ClinicalTrials.gov, NCT05507411, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT05507411, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.